Woodlands, Texas-based biopharmaceutical company Lexicon Pharmaceuticals recently announced new additions to the company’s management team in order to enhance and accelerate the research program for the development and commercial preparation of telotristat etiprate, a therapy for carcinoid syndrome, as well as the commercial preparation of sotagliflozin (LX4211) for type 1 diabetes, which are both in phase III of development.
Kenneth B. Kassler-Taub, M.D. will serve as the company’s new vice president of clinical operations, and will be responsible for leading Lexicon’s ongoing clinical trials. During his 25-year career, he has held key management positions, such as his most recent role as vice-president of corporate clinical development, overseeing the company-wide clinical development at Becton Dickinson and Company, where he had previously served as worldwide vice president of medical affairs in the BD Medical Segment. Previously, Kassler-Taub worked for 14 years at Bristol-Myers Squibb Company and received numerous promotions while there.
“The addition of Dr. Kassler-Taub further strengthens our organization in clinical operations as we make our final push toward completion of our Phase 3 program for telotristat etiprate in carcinoid syndrome and begin our Phase 3 program with sotagliflozin (LX4211) in type 1 diabetes,” said the president and chief executive officer of Lexicon, Lonnel Coats.
In addition, Lexicon also added Kiernan A. Seth, Ph.D., MBA, who has joined the company as the new executive director of marketing. With 19 years of experience, Dr. Seth is expected to contribute to the advancement of Lexicon’s commercial readiness under the supervision of John Northcott, Lexicon’s vice president of marketing, commercial strategy, and operations. “Dr. Seth will be a great complement to our commercial team as we establish Lexicon’s commercial presence,” Coats added.
Seth previously served as executive director of Eisai Value Maximization Systems and head of the oncology business unit at Eisai, Inc. In addition, he was also part of the marketing departments of companies like Bristol-Myers Squibb, Pfizer, and Schering-Plough, with a focus in oncology, cardiovascular and metabolic disease, immunology and central nervous system products.
These new appointments join other recent additions to the Lexicon staff, such as the addition of current president and CEO Lonnel Coats, who left his 18-year position as CEO of Eisai’s United States subsidiary to join Lexicon this past July. The company’s staff changes coincide with Lexicon’s refocusing on completing its multi-disease, late-stage drug development programs, as earlier in the year, Lexicon decided to reduce staff to be fully dedicated to developing and commercializing both telotristat etiprate and sotagliflozin.